Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hazard Rate01:11

Hazard Rate

The hazard rate, also known as the hazard function or failure rate, is a statistical measure used to describe the instantaneous rate at which an event occurs, given that the event has not yet happened. From a probabilistic perspective, it represents the likelihood that a subject will experience the event in a very small time interval, conditional on surviving up to the beginning of that interval. In terms of frequency, the hazard rate can be viewed as the ratio of the number of events to the...
Hazard Ratio01:12

Hazard Ratio

The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial evaluating a...
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Relative Risk01:12

Relative Risk

Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
Design Example: Analyzing Capacity Contours for Flood Risk Assessment01:17

Design Example: Analyzing Capacity Contours for Flood Risk Assessment

Flood risk assessment involves careful planning and analysis to ensure the safety of communities near water retention structures. Capacity contours are a vital tool in this process, as they illustrate the potential spread of water at specific levels in a given area. In the context of building a bund across a small valley, these contours play a critical role in evaluating the safety of nearby residential areas.In this example, the bund is intended to store stormwater in the valley. The engineers...
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence of plasma lipid disorders with an emphasis on LDL cholesterol in selected countries in the Asia-Pacific region.

Lipids in health and disease·2021
Same author

Waist circumference as a vital sign in clinical practice: a Consensus Statement from the IAS and ICCR Working Group on Visceral Obesity.

Nature reviews. Endocrinology·2020
Same author

Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement.

The lancet. Diabetes & endocrinology·2019
Same author

HDL cholesterol and ASCVD risk stratification: A debate.

Atherosclerosis·2019
Same author

Expert opinion on the applicability of dyslipidemia guidelines in Asia and the Middle East.

International journal of general medicine·2018
Same author

Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial.

Circulation·2018
Same journal

'Diet and lifestyle' in the management of dyslipidaemia and prevention of CVD - Understanding the level of knowledge and interest of European Atherosclerosis Society members.

Atherosclerosis. Supplements·2021
Same journal

Improving lipid management in patients with acute coronary syndrome: The ACS Lipid EuroPath tool.

Atherosclerosis. Supplements·2021
Same journal

Lipid Clinics Network. Rationale and design of the EAS global project.

Atherosclerosis. Supplements·2021
Same journal

Implementation of clinical practices and pathways optimizing ACS patients lipid management: Focus on eight European initiatives.

Atherosclerosis. Supplements·2021
Same journal

Lipid-lowering therapy and low-density lipoprotein cholesterol goal achievement in patients with acute coronary syndromes: The ACS patient pathway project.

Atherosclerosis. Supplements·2021
Same journal

Prevalence and relationship between metabolic syndrome and risk of cardiovascular disease: Evidence from two population-based studies.

Atherosclerosis. Supplements·2021
See all related articles

Related Experiment Videos

HDL-C: role as a risk modifier.

Philip Barter1

  • 1The Heart Research Institute, 7 Eliza Street, Newtown, Sydney, NSW 2050, Australia. barterp@hri.org.au

Atherosclerosis. Supplements
|December 14, 2011
PubMed
Summary
This summary is machine-generated.

Lowering LDL-C with statins reduces cardiovascular risk, but residual risk persists. Increasing HDL-C levels offers a promising strategy to further reduce cardiovascular disease risk, especially in high-risk patients.

Related Experiment Videos

Area of Science:

  • Cardiology
  • Metabolic Syndrome
  • Pharmacology

Background:

  • Low-density lipoprotein-cholesterol (LDL-C) is a primary driver of cardiovascular disease (CVD).
  • Statins effectively lower LDL-C and reduce CVD risk, yet a significant residual risk remains in many patients.
  • Low high-density lipoprotein-cholesterol (HDL-C) levels are independently associated with increased CVD risk, even with optimized LDL-C.

Purpose of the Study:

  • To evaluate the role of high-density lipoprotein-cholesterol (HDL-C) in residual cardiovascular risk.
  • To explore the therapeutic potential of increasing HDL-C levels for reducing residual CVD risk.
  • To examine the combined impact of LDL-C and HDL-C levels on cardiovascular outcomes.

Main Methods:

  • Review of existing evidence on LDL-C and HDL-C in cardiovascular disease.
  • Analysis of studies investigating HDL-C functions beyond cholesterol efflux (e.g., anti-inflammatory, anti-oxidative).
  • Examination of data from clinical trials and meta-analyses assessing HDL-C-raising strategies and their impact on atheroma progression and CV events.

Main Results:

  • Low HDL-C levels are a significant predictor of CVD risk, independent of LDL-C levels, even when LDL-C is below 1.8 mmol/L.
  • HDL particles possess multiple atheroprotective properties, including anti-oxidation, reduced vascular inflammation, and improved endothelial function.
  • Studies indicate that increasing HDL-C levels, potentially through statin therapy or other interventions, contributes to additional cardiovascular risk reduction.

Conclusions:

  • Targeting both LDL-C and HDL-C is crucial for comprehensive cardiovascular risk management.
  • Increasing HDL-C levels represents a viable therapeutic strategy to address residual CVD risk in patients with dyslipidemia.
  • Further research and clinical strategies focusing on raising HDL-C are warranted for high-risk individuals.